|
R30-m2
|
IIEQPKQrGMRFRYK
|
Upstream
|
Downstream
|
1
|
0
|
|
|
|
Effects on Biological Processes:
- cell adhesion, induced
- transcription, induced
|
|
|
Regulatory protein:
|
|
Treatment
|
|
|
NFkB-p65 (human)
|
IIEQPKQRGMRFRYk
|
R30
|
|
NFkB-p65 (mouse)
|
IIEQPKQRGMRFRYK
|
R30
|
|
NFkB-p65 (rat)
|
IIEQPKQrGMRFRYK
|
R30-m2
|
|
|
K37
|
rGMRFRYKCEGRSAG
|
|
|
2
|
0
|
|
|
|
NFkB-p65 (human)
|
RGMRFRYkCEGRsAG
|
K37-me
|
|
NFkB-p65 (mouse)
|
RGMRFRYKCEGRSAG
|
K37
|
|
NFkB-p65 (rat)
|
rGMRFRYKCEGRSAG
|
K37
|
|
|
K37
|
rGMRFRYKCEGRSAG
|
|
|
1
|
0
|
|
|
|
NFkB-p65 (human)
|
RGMRFRYkCEGRsAG
|
K37-m1
|
|
NFkB-p65 (mouse)
|
RGMRFRYKCEGRSAG
|
K37
|
|
NFkB-p65 (rat)
|
rGMRFRYKCEGRSAG
|
K37
|
|
|
S42
|
RYKCEGRSAGSIPGE
|
|
|
1
|
3
|
|
|
|
NFkB-p65 (human)
|
RYkCEGRsAGsIPGE
|
S42-p
|
|
NFkB-p65 (mouse)
|
RYKCEGRSAGsIPGE
|
S42
|
|
NFkB-p65 (rat)
|
RYKCEGRSAGSIPGE
|
S42
|
|
|
S45
|
CEGRSAGSIPGERST
|
|
|
1
|
9
|
|
|
|
NFkB-p65 (human)
|
CEGRsAGsIPGERST
|
S45-p
|
|
NFkB-p65 (mouse)
|
CEGRSAGsIPGERST
|
S45-p
|
|
NFkB-p65 (rat)
|
CEGRSAGSIPGERST
|
S45
|
|
|
K56
|
ERSTDTTKTHPTIKI
|
|
|
1
|
2
|
|
|
|
NFkB-p65 (human)
|
ERSTDTTkTHPTIkI
|
K56-ub
|
|
NFkB-p65 (mouse)
|
ERSTDTTKTHPTIKI
|
K56
|
|
NFkB-p65 (rat)
|
ERSTDTTKTHPTIKI
|
K56
|
|
|
K62
|
TKTHPTIKINGYTGP
|
|
|
2
|
1
|
|
|
|
NFkB-p65 (human)
|
TkTHPTIkINGYTGP
|
K62-ub
|
|
NFkB-p65 (mouse)
|
TKTHPTIKINGYTGP
|
K62
|
|
NFkB-p65 (rat)
|
TKTHPTIKINGYTGP
|
K62
|
|
|
T71
|
NGYTGPGTVRISLVT
|
|
|
0
|
1
|
|
|
|
NFkB-p65 (human)
|
NGYTGPGtVRISLVT
|
T71-p
|
|
NFkB-p65 (mouse)
|
NGYTGPGTVRISLVT
|
T71
|
|
NFkB-p65 (rat)
|
NGYTGPGTVRISLVT
|
T71
|
|
|
K79
|
VRISLVTKDPPHRPH
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
VRISLVTkDPPHRPH
|
K79-ub
|
|
NFkB-p65 (mouse)
|
VRISLVTKDPPHRPH
|
K79
|
|
NFkB-p65 (rat)
|
VRISLVTKDPPHRPH
|
K79
|
|
|
K93
|
HPHELVGKDCRDGFY
|
|
|
0
|
1
|
|
|
|
NFkB-p65 (human)
|
HPHELVGkDCRDGFY
|
K93-ub
|
|
NFkB-p65 (mouse)
|
HPHELVGKDCRDGyY
|
K93
|
|
NFkB-p65 (rat)
|
HPHELVGKDCRDGFY
|
K93
|
|
|
F99
|
GKDCRDGFYEAELCP
|
|
|
0
|
2
|
|
|
|
NFkB-p65 (human)
|
GkDCRDGFYEAELCP
|
F99
|
|
NFkB-p65 (mouse)
|
GKDCRDGyYEADLCP
|
Y99-p
|
|
NFkB-p65 (rat)
|
GKDCRDGFYEAELCP
|
F99
|
|
|
C109
|
AELCPDRCIHSFQNL
|
|
|
0
|
1
|
|
|
|
NFkB-p65 (human)
|
AELCPDRCIHsFQNL
|
C109
|
|
NFkB-p65 (mouse)
|
ADLCPDRsIHsFQNL
|
S109-p
|
|
NFkB-p65 (rat)
|
AELCPDRCIHSFQNL
|
C109
|
|
|
S112
|
CPDRCIHSFQNLGIQ
|
|
|
0
|
2
|
|
|
|
|
|
K122
|
NLGIQCVKKRDLEQA
|
|
|
6
|
26
|
|
|
|
|
|
K122
|
NLGIQCVKKRDLEQA
|
|
|
2
|
2
|
|
|
|
NFkB-p65 (human)
|
NLGIQCVkkRDLEQA
|
K122-ub
|
|
NFkB-p65 (mouse)
|
NLGIQCVKkRDLEQA
|
K122
|
|
NFkB-p65 (rat)
|
NLGIQCVKKRDLEQA
|
K122
|
|
|
K123
|
LGIQCVKKRDLEQAI
|
|
|
4
|
0
|
|
|
|
|
|
K123
|
LGIQCVKKRDLEQAI
|
|
|
1
|
2
|
|
|
|
|
|
S131
|
RDLEQAISQRIQTNN
|
|
|
1
|
3
|
|
|
|
|
|
T136
|
AISQRIQTNNNPFQV
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
AIsQRIQtNNNPFQV
|
T136-p
|
|
NFkB-p65 (mouse)
|
AIsQRIQTNNNPFHV
|
T136
|
|
NFkB-p65 (rat)
|
AISQRIQTNNNPFQV
|
T136
|
|
|
R174
|
DPSGRPLRLTPVLSH
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
DPSGRPLrLPPVLsH
|
R174-m2
|
|
NFkB-p65 (mouse)
|
DPAGRPLLLtPVLSH
|
L174
|
|
NFkB-p65 (rat)
|
DPSGRPLRLTPVLSH
|
R174
|
|
|
T176
|
SGRPLRLTPVLSHPI
|
|
|
0
|
4
|
|
|
|
NFkB-p65 (human)
|
SGRPLrLPPVLsHPI
|
P176
|
|
NFkB-p65 (mouse)
|
AGRPLLLtPVLSHPI
|
T176-p
|
|
NFkB-p65 (rat)
|
SGRPLRLTPVLSHPI
|
T176
|
|
|
S180
|
LRLTPVLSHPIFDNR
|
|
|
0
|
2
|
|
|
|
NFkB-p65 (human)
|
LrLPPVLsHPIFDNr
|
S180-p
|
|
NFkB-p65 (mouse)
|
LLLtPVLSHPIFDNR
|
S180
|
|
NFkB-p65 (rat)
|
LRLTPVLSHPIFDNR
|
S180
|
|
|
R187
|
SHPIFDNRAPNTAEL
|
|
|
0
|
1
|
|
|
|
NFkB-p65 (human)
|
sHPIFDNrAPNTAEL
|
R187-m1
|
|
NFkB-p65 (mouse)
|
SHPIFDNRAPNTAEL
|
R187
|
|
NFkB-p65 (rat)
|
SHPIFDNRAPNTAEL
|
R187
|
|
|
K195
|
APNTAELKICRVNRN
|
|
|
2
|
2
|
|
|
|
NFkB-p65 (human)
|
APNTAELkICRVNRN
|
K195-ub
|
|
NFkB-p65 (mouse)
|
APNTAELKICRVNRN
|
K195
|
|
NFkB-p65 (rat)
|
APNTAELKICRVNRN
|
K195
|
|
|
S203
|
ICRVNRNSGSCLGGD
|
|
|
0
|
1
|
|
|
|
NFkB-p65 (human)
|
ICRVNRNSGsCLGGD
|
S203
|
|
NFkB-p65 (mouse)
|
ICRVNRNsGsCLGGD
|
S203-p
|
|
NFkB-p65 (rat)
|
ICRVNRNSGSCLGGD
|
S203
|
|
|
S205
|
RVNRNSGSCLGGDEI
|
|
|
4
|
1
|
|
|
|
|
|
K218
|
EIFLLCDKVQKEDIE
|
|
|
6
|
0
|
|
|
|
|
|
K218
|
EIFLLCDKVQKEDIE
|
|
|
1
|
0
|
|
|
|
NFkB-p65 (human)
|
EIFLLCDkVQkEDIE
|
K218-me
|
|
NFkB-p65 (mouse)
|
EIFLLCDKVQkEDIE
|
K218
|
|
NFkB-p65 (rat)
|
EIFLLCDKVQKEDIE
|
K218
|
|
|
K221
|
LLCDKVQKEDIEVYF
|
|
|
11
|
0
|
|
|
|
|
|
K221
|
LLCDKVQKEDIEVYF
|
|
|
1
|
0
|
|
|
|
NFkB-p65 (human)
|
LLCDkVQkEDIEVYF
|
K221-me
|
|
NFkB-p65 (mouse)
|
LLCDkVQKEDIEVYF
|
K221
|
|
NFkB-p65 (rat)
|
LLCDKVQKEDIEVYF
|
K221
|
|
|
S238
|
PGWEARGSFSQADVH
|
|
|
1
|
10
|
|
|
|
|
|
T254-p
|
QVAIVFRtPPyADPS
|
Upstream
|
|
6
|
1
|
|
|
|
|
|
|
|
Y257-p
|
IVFRtPPyADPSLQA
|
|
|
0
|
1
|
|
|
|
NFkB-p65 (human)
|
IVFRtPPYADPsLQA
|
Y257
|
|
NFkB-p65 (mouse)
|
IVFRTPPYADPsLQA
|
Y257
|
|
NFkB-p65 (rat)
|
IVFRtPPyADPSLQA
|
Y257-p
|
|
|
S261
|
tPPyADPSLQAPVRV
|
|
|
1
|
2
|
|
|
|
|
|
S269
|
LQAPVRVSMQLRRPs
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
LQAPVRVsMQLRRPs
|
S269-p
|
|
NFkB-p65 (mouse)
|
LQAPVRVSMQLRRPs
|
S269
|
|
NFkB-p65 (rat)
|
LQAPVRVSMQLRRPs
|
S269
|
|
|
S276-p
|
SMQLRRPsDRELSEP
|
Upstream
|
Downstream
|
90
|
0
|
|
|
|
Effects on Biological Processes:
- apoptosis, inhibited
- cell differentiation, altered
- transcription, induced
|
|
|
Putative in vivo kinases:
- PKACA (human)
- PKACA (rat)
|
|
Treatment
- cAMP_analog
- cholinergic_lesion
- colforsin
- H-89
- JQ1
- leptin
- levodopa
- siRNA
- status epilepticus
- virus infection
|
|
|
|
|
S281
|
RPsDRELSEPMEFQY
|
|
|
6
|
0
|
|
|
|
NFkB-p65 (human)
|
RPsDRELsEPMEFQY
|
S281-p
|
|
NFkB-p65 (mouse)
|
RPsDRELSEPMEFQY
|
S281
|
|
NFkB-p65 (rat)
|
RPsDRELSEPMEFQY
|
S281
|
|
|
T305
|
IEEKRKRTYETFksI
|
|
|
1
|
2
|
|
|
|
NFkB-p65 (human)
|
IEEKRKRtyEtFksI
|
T305-p
|
|
NFkB-p65 (mouse)
|
IEEKRKRTYETFksI
|
T305
|
|
NFkB-p65 (rat)
|
IEEKRKRTYETFksI
|
T305
|
|
|
T305
|
IEEKRKRTYETFksI
|
|
|
2
|
1
|
|
|
|
NFkB-p65 (human)
|
IEEKRKRtyEtFksI
|
T305-gl
|
|
NFkB-p65 (mouse)
|
IEEKRKRTYETFksI
|
T305
|
|
NFkB-p65 (rat)
|
IEEKRKRTYETFksI
|
T305
|
|
|
Y306
|
EEKRKRTYETFksIM
|
|
|
0
|
2
|
|
|
|
NFkB-p65 (human)
|
EEKRKRtyEtFksIM
|
Y306-p
|
|
NFkB-p65 (mouse)
|
EEKRKRTYETFksIM
|
Y306
|
|
NFkB-p65 (rat)
|
EEKRKRTYETFksIM
|
Y306
|
|
|
T308
|
KRKRTYETFksIMKK
|
|
|
1
|
2
|
|
|
|
NFkB-p65 (human)
|
KRKRtyEtFksIMkk
|
T308-p
|
|
NFkB-p65 (mouse)
|
KRKRTYETFksIMKK
|
T308
|
|
NFkB-p65 (rat)
|
KRKRTYETFksIMKK
|
T308
|
|
|
K310-ac
|
KRTYETFksIMKKSP
|
Upstream
|
Downstream
|
81
|
6
|
|
|
|
|
|
Effects on Modified Protein
- intracellular localization
- molecular association, regulation
|
|
Effects on Biological Processes:
|
|
|
Regulatory protein:
|
|
Treatment
- fluid replacement
- fructose
- IL-1b
- Lactobacillus-containing probiotics
- palmitate
- PGRN
- resveratrol
- selisistat
- siRNA
- TNF
- traumatic hemorrhagic shock
|
|
|
|
|
K310
|
KRTYETFKsIMKKSP
|
|
|
1
|
0
|
|
|
|
NFkB-p65 (human)
|
KRtyEtFksIMkksP
|
K310-me
|
|
NFkB-p65 (mouse)
|
KRTYETFKsIMKKSP
|
K310
|
|
NFkB-p65 (rat)
|
KRTYETFKsIMKKSP
|
K310
|
|
|
K310
|
KRTYETFKsIMKKSP
|
|
|
2
|
1
|
|
|
|
|
|
NFkB-p65 (human)
|
KRtyEtFksIMkksP
|
K310-m1
|
|
NFkB-p65 (mouse)
|
KRTYETFKsIMKKSP
|
K310
|
|
NFkB-p65 (rat)
|
KRTYETFKsIMKKSP
|
K310
|
|
|
K310
|
KRTYETFKsIMKKSP
|
|
|
1
|
2
|
|
|
|
NFkB-p65 (human)
|
KRtyEtFksIMkksP
|
K310-ub
|
|
NFkB-p65 (mouse)
|
KRTYETFKsIMKKSP
|
K310
|
|
NFkB-p65 (rat)
|
KRTYETFKsIMKKSP
|
K310
|
|
|
S311-p
|
RTYETFksIMKKSPF
|
Upstream
|
Downstream
|
17
|
3
|
|
|
|
Effects on Biological Processes:
|
|
|
Treatment
- calciol
- glucosamine
- prednisolone
- PUGNAc
- status epilepticus
- TNF
|
|
|
|
|
K314
|
ETFksIMKKSPFNGP
|
|
|
7
|
1
|
|
|
|
NFkB-p65 (human)
|
EtFksIMkksPFsGP
|
K314-ac
|
|
NFkB-p65 (mouse)
|
ETFksIMKKSPFNGP
|
K314
|
|
NFkB-p65 (rat)
|
ETFksIMKKSPFNGP
|
K314
|
|
|
K314
|
ETFksIMKKSPFNGP
|
|
|
2
|
1
|
|
|
|
NFkB-p65 (human)
|
EtFksIMkksPFsGP
|
K314-m1
|
|
NFkB-p65 (mouse)
|
ETFksIMKKSPFNGP
|
K314
|
|
NFkB-p65 (rat)
|
ETFksIMKKSPFNGP
|
K314
|
|
|
K314
|
ETFksIMKKSPFNGP
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
EtFksIMkksPFsGP
|
K314-ub
|
|
NFkB-p65 (mouse)
|
ETFksIMKKSPFNGP
|
K314
|
|
NFkB-p65 (rat)
|
ETFksIMKKSPFNGP
|
K314
|
|
|
K315
|
TFksIMKKSPFNGPT
|
|
|
7
|
1
|
|
|
|
NFkB-p65 (human)
|
tFksIMkksPFsGPt
|
K315-ac
|
|
NFkB-p65 (mouse)
|
TFksIMKKSPFNGPT
|
K315
|
|
NFkB-p65 (rat)
|
TFksIMKKSPFNGPT
|
K315
|
|
|
K315
|
TFksIMKKSPFNGPT
|
|
|
2
|
1
|
|
|
|
NFkB-p65 (human)
|
tFksIMkksPFsGPt
|
K315-m1
|
|
NFkB-p65 (mouse)
|
TFksIMKKSPFNGPT
|
K315
|
|
NFkB-p65 (rat)
|
TFksIMKKSPFNGPT
|
K315
|
|
|
K315
|
TFksIMKKSPFNGPT
|
|
|
1
|
2
|
|
|
|
NFkB-p65 (human)
|
tFksIMkksPFsGPt
|
K315-ub
|
|
NFkB-p65 (mouse)
|
TFksIMKKSPFNGPT
|
K315
|
|
NFkB-p65 (rat)
|
TFksIMKKSPFNGPT
|
K315
|
|
|
S316
|
FksIMKKSPFNGPTE
|
|
|
1
|
3
|
|
|
|
NFkB-p65 (human)
|
FksIMkksPFsGPtD
|
S316-p
|
|
NFkB-p65 (mouse)
|
FksIMKKSPFNGPTE
|
S316
|
|
NFkB-p65 (rat)
|
FksIMKKSPFNGPTE
|
S316
|
|
|
N319
|
IMKKSPFNGPTEPRP
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
IMkksPFsGPtDPRP
|
S319-gl
|
|
NFkB-p65 (mouse)
|
IMKKSPFNGPTEPRP
|
N319
|
|
NFkB-p65 (rat)
|
IMKKSPFNGPTEPRP
|
N319
|
|
|
T322
|
KSPFNGPTEPRPPPR
|
|
|
3
|
1
|
|
|
|
NFkB-p65 (human)
|
ksPFsGPtDPRPPPR
|
T322-gl
|
|
NFkB-p65 (mouse)
|
KSPFNGPTEPRPPTR
|
T322
|
|
NFkB-p65 (rat)
|
KSPFNGPTEPRPPPR
|
T322
|
|
|
G337
|
RIAVPSRGPTSVPKP
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
RIAVPSRsSASVPKP
|
S337-gl
|
|
NFkB-p65 (mouse)
|
RIAVPTRNSTSVPKP
|
N337
|
|
NFkB-p65 (rat)
|
RIAVPSRGPTSVPKP
|
G337
|
|
|
S352
|
APQPYAFSTSLSTIN
|
|
|
3
|
2
|
|
|
|
NFkB-p65 (human)
|
APQPYPFtSSLSTIN
|
T352-gl
|
|
NFkB-p65 (mouse)
|
APQPYTFPASLSTIN
|
P352
|
|
NFkB-p65 (rat)
|
APQPYAFSTSLSTIN
|
S352
|
|
|
S374
|
VLPPGQISNQALALA
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
VFPSGQIsQAsALAP
|
S374-gl
|
|
NFkB-p65 (mouse)
|
LLPSGQISNQALALA
|
S374
|
|
NFkB-p65 (rat)
|
VLPPGQISNQALALA
|
S374
|
|
|
L378
|
GQISNQALALAPSSA
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
SGQIsQAsALAPAPP
|
S377-gl
|
|
NFkB-p65 (mouse)
|
GQISNQALALAPSSA
|
L378
|
|
NFkB-p65 (rat)
|
GQISNQALALAPSSA
|
L378
|
|
|
T434
|
STQAGEGTLSEALLH
|
|
|
2
|
0
|
|
|
|
NFkB-p65 (human)
|
PTQAGEGtLSEALLQ
|
T435-p
|
|
NFkB-p65 (mouse)
|
STQAGEGTLSEALLH
|
T433
|
|
NFkB-p65 (rat)
|
STQAGEGTLSEALLH
|
T434
|
|
|
S468-p
|
GVFTDLAsVDNSEFQ
|
Upstream
|
Downstream
|
21
|
0
|
|
|
|
|
|
Effects on Biological Processes:
|
|
|
Treatment
- status epilepticus
- titanium dioxide nanoparticles
|
|
|
|
|
S472
|
DLAsVDNSEFQQLLN
|
|
|
1
|
1
|
|
|
|
NFkB-p65 (human)
|
DLAsVDNsEFQQLLN
|
S472-p
|
|
NFkB-p65 (mouse)
|
DLAsVDNSEFQQLLN
|
S471
|
|
NFkB-p65 (rat)
|
DLAsVDNSEFQQLLN
|
S472
|
|
|
T505
|
EAITRLVTGSQRPPD
|
|
|
4
|
0
|
|
|
|
|
|
S528-p
|
SGLPNGLsGDEDFSs
|
Upstream
|
Downstream
|
27
|
4
|
|
|
|
|
|
Effects on Biological Processes:
|
|
|
Putative in vivo kinases:
|
|
Treatment
- 3CAI
- NAC
- status epilepticus
- TMCB
- TNF
|
|
|
|
|
S534
|
LsGDEDFSsIADMDF
|
|
|
0
|
1
|
|
|
|
NFkB-p65 (human)
|
LsGDEDFSsIADMDF
|
S535
|
|
NFkB-p65 (mouse)
|
LsGDEDFssIADMDF
|
S533-p
|
|
NFkB-p65 (rat)
|
LsGDEDFSsIADMDF
|
S534
|
|
|
S535-p
|
sGDEDFSsIADMDFS
|
Upstream
|
Downstream
|
261
|
4
|
|
|
|
|
|
Effects on Biological Processes:
- apoptosis, induced
- apoptosis, inhibited
- autophagy, induced
- signaling pathway regulation
- transcription, induced
|
|
|
Putative in vivo kinases:
|
|
Putative upstream phosphatases:
|
|
Regulatory protein:
- IKKB (rat)
- RHOA (human)
- SMAD7 (human)
- TLR4 (human)
- TNC (human)
|
|
Treatment
- 3CAI
- 5-ASA
- angiotensin
- angiotensin_2
- conditioned medium
- EGCG
- EHOP-016
- EHT-1864
- exoenzyme_C3
- fluid replacement
- glucosamine
- high_glucose
- hypertonic_buffer
- JQ1
- L-788,123
- Lactobacillus-containing probiotics
- levodopa
- low_glucose
- metformin
- miR-155-5p
- mtDNA
- NAC
- NSC23766
- PD98059
- PUGNAc
- simvastatin
- siRNA
- status epilepticus
- taurine_chloramine
- TGF-beta
- titanium dioxide nanoparticles
- TMCB
- TNF
- traumatic hemorrhagic shock
- U0126
|
|
|
|
|
S546
|
MDFSALLSQISS___
|
|
|
1
|
1
|
|
|
|
|
